MDM2 and neoplasm: CGM097 alone at 50 mg/kg/day demonstrated no inhibition of tumor growth in these models (Figure 3A and Figure 3—source data 1), suggesting that single-agent treatment with MDM2 inhibitors is not sufficient to inhibit the growth of TP53 wild-type neuroblastoma tumors expressing wild-type or activated ALK.